TapImmune, Inc. (NASDAQ: TPIV), a clinical- stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease today announced the opening of its Phase 2 company-sponsored ovarian cancer study in platinum-sensitive ovarian cancer patients.
Read More »
Closer to the Finish! DONNA partner TapImmune announced that its common stock has been approved to begin trading on The Nasdaq Capital Market. The company’s common stock will begin trading under the symbol “TPIV” at the opening of trading on Tuesday, November 8, 2016.
Closer to the Finish! DONNA partner TapImmune announces the commercialization pathway for its HER2neu Vaccine and the initiation of company-sponsored Phase 2 Clinical Trials that will start early 2017. In a Phase I clinical trial on the four Class II antigens in HER2neu breast cancer patients performed at the Mayo Clinic.
Closer to the Finish! DONNA partner TapImmune issued an update to shareholders September 6 announcing the commencement of enrollment of patients in Q4 2016 for the Phase 2 study of TPIV 200 in the treatment of triple negative breast cancer.
DONNA partner TapImmune announced its plans to enter into definitive agreements to raise aggregate gross proceeds of approximately $8.5 million from an approximately $2.5 million private placement transaction with new investors and the exercise of certain outstanding warrants from existing investors that will result in gross proceeds of $6 million.
DONNA partner TapImmune announced a major milestone of dosing its first patient in a Phase 2 trial for triple negative breast cancer with its cancer vaccine TPIV 200. The randomized, open label Phase 2 study is expected to enroll a total of 80 subjects. Go Team Go!
ABC TV News Anchor, Laura Harris interviews Dr. Glynn Wilson of Tapimmune Inc., on $13.3 million grant from the US Department of Defense Breast Cancer Research Program to Dr Keith Knutson and Dr Edith Perez at the Mayo Clinic, Jacksonville, FL. This grant will completely fund a large (280 patient) study […]
“This is just the beginning and it’s why supporting 26.2 with DONNA is so important. We need to continue to fund each of these ideas as they come to our brilliant researchers so we can cure breast cancer.” – Donna Deegan JACKSONVILLE, Fla. — Researchers on Mayo Clinic’s Florida campus have been awarded a $13.3 million, five-year Read More >>